FR2950350B1 - Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations - Google Patents

Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Info

Publication number
FR2950350B1
FR2950350B1 FR0904576A FR0904576A FR2950350B1 FR 2950350 B1 FR2950350 B1 FR 2950350B1 FR 0904576 A FR0904576 A FR 0904576A FR 0904576 A FR0904576 A FR 0904576A FR 2950350 B1 FR2950350 B1 FR 2950350B1
Authority
FR
France
Prior art keywords
exosomes
polypeptide
concerns
present
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0904576A
Other languages
English (en)
French (fr)
Other versions
FR2950350A1 (fr
Inventor
Robert Zaine El Abiddine Mamoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Montpellier
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Priority to FR0904576A priority Critical patent/FR2950350B1/fr
Priority to US13/497,779 priority patent/US9611481B2/en
Priority to EP10769025.7A priority patent/EP2480672B8/fr
Priority to PCT/FR2010/052006 priority patent/WO2011036416A1/fr
Priority to JP2012530319A priority patent/JP5932647B2/ja
Priority to CA2775151A priority patent/CA2775151C/fr
Publication of FR2950350A1 publication Critical patent/FR2950350A1/fr
Application granted granted Critical
Publication of FR2950350B1 publication Critical patent/FR2950350B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0904576A 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations Active FR2950350B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0904576A FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
US13/497,779 US9611481B2 (en) 2009-09-24 2010-09-23 Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
EP10769025.7A EP2480672B8 (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
PCT/FR2010/052006 WO2011036416A1 (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
JP2012530319A JP5932647B2 (ja) 2009-09-24 2010-09-23 エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用
CA2775151A CA2775151C (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0904576A FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Publications (2)

Publication Number Publication Date
FR2950350A1 FR2950350A1 (fr) 2011-03-25
FR2950350B1 true FR2950350B1 (fr) 2013-12-13

Family

ID=42107419

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0904576A Active FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Country Status (6)

Country Link
US (1) US9611481B2 (cg-RX-API-DMAC7.html)
EP (1) EP2480672B8 (cg-RX-API-DMAC7.html)
JP (1) JP5932647B2 (cg-RX-API-DMAC7.html)
CA (1) CA2775151C (cg-RX-API-DMAC7.html)
FR (1) FR2950350B1 (cg-RX-API-DMAC7.html)
WO (1) WO2011036416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512680A (ja) * 2013-03-15 2016-05-09 ノババックス,インコーポレイテッド ピコルナウイルス(Picornavirus)タンパク質の発現増強
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
PL228341B1 (pl) * 2014-04-21 2018-03-30 Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
AU2017335084B2 (en) * 2016-09-30 2023-06-29 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
EP4059510B1 (en) 2018-11-16 2025-05-21 Lonza Sales AG Engineered extracellular vesicles and uses thereof
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020215010A1 (en) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
EP3973969A4 (en) * 2019-09-02 2023-07-12 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IL-2 EXTRACELLULAR SURFACE EXPRESSION VESICLES AS AN ACTIVE AGENT
WO2021144363A1 (en) 2020-01-14 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic reactivity of a peptide mimicking the glycan loop of flaviviruses envelope protein
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ,インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
KR20220139926A (ko) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 인공 시냅스
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
EP4138907A4 (en) * 2020-04-20 2024-08-21 The General Hospital Corporation IMMUNOGENIC COMPOSITION OF CORONAVIRUS WITH EPITOPES HAVING HIGH NETWORK SCORE
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN116194462B (zh) * 2020-08-11 2025-07-18 庆北大学校产学协力团 选择性结合癌细胞来源外泌体的肽及其用途
EP3973985A1 (en) * 2020-09-29 2022-03-30 Ciloa Extracellular vesicles harboring a spike protein, nucleic acids for producing the same, and method of immunizing a subject against sars-cov-2 using the same
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品
CA3255140A1 (en) 2022-05-20 2023-11-23 Ciloa REVERSIBLE LOADING OF PROTEINS IN THE LUMINUM OF EXTRACELLULAR VESICLES
EP4612190A2 (en) * 2022-11-02 2025-09-10 Pioneer Biolabs, LLC Systems and methods for single cell detection of protein secretion
CN121646610A (zh) * 2023-06-05 2026-03-10 希洛欧公司 嵌合多肽、包含嵌合多肽的胞外囊泡及其用途
WO2026022863A1 (en) * 2024-07-25 2026-01-29 Christian Medical College Extracellular vesicles and uses thereof for targeted delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417229B1 (en) * 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
JP2005528091A (ja) 2002-03-14 2005-09-22 アノシス・インコーポレーテッド T細胞由来小胞の機能化、および免疫原性医薬組成物を製造するためのその使用
WO2004073319A2 (en) * 2003-02-14 2004-08-26 Anosys, Inc. Methods and compounds for raising antibodies and for screening antibody repertoires
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes

Also Published As

Publication number Publication date
WO2011036416A1 (fr) 2011-03-31
EP2480672A1 (fr) 2012-08-01
CA2775151A1 (fr) 2011-03-31
US9611481B2 (en) 2017-04-04
US20120321653A1 (en) 2012-12-20
FR2950350A1 (fr) 2011-03-25
JP2013505713A (ja) 2013-02-21
CA2775151C (fr) 2019-01-22
EP2480672B8 (fr) 2017-03-22
JP5932647B2 (ja) 2016-06-08
EP2480672B1 (fr) 2016-12-28

Similar Documents

Publication Publication Date Title
AU2017248555B2 (en) Closed nucleic acid structures
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
MX375482B (es) Composición y método para estabilizar ácidos nucleicos en muestras biológicas.
ZA201902654B (en) In vitro and cell based assays for measuring the activity of botulinum neurotoxins
PH12012502272A1 (en) Biological materials related to her3
MX2016003945A (es) Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias.
WO2009120374A3 (en) Methods and compositions for nucleic acid sample preparation
EA201171220A1 (ru) Мутанты fgf21 и их применение
MY156286A (en) Human il-23 antigen binding proteins
UY32477A (es) Proteínas de unión a il-17
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
MX392780B (es) Polinucléotidos que condifican anticuerpos de oncostatina m humana
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
PH12012500816A1 (en) Modified oil encapsulating proteins and uses thereof
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
ATE549410T1 (de) Kontrollierte aktivierung von nicht-ltr- retrotransposonen bei säugetieren
MX2018013875A (es) Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa.
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2016036635A8 (en) Chromobacterium subtsugae genes
MY148542A (en) A method for the assessment of cancer in a biological sample obtained from a subject
MX2018014434A (es) Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa.

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 8

TQ Partial transmission of property

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20170510

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20170510

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17